SNC115
/ Shanghai Simnova Bio
- LARVOL DELTA
Home
Next
Prev
1 to 3
Of
3
Go to page
1
February 05, 2026
SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): Safety, pharmacokinetic, and preliminary efficacy results from a phase 1 study
(ELCC 2026)
- No abstract available
Clinical • P1 data • PK/PD data • Large Cell Carcinoma • Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor
October 04, 2025
SNC115 in patients with relapsed/refractory small cell lung cancer (SCLC) and large cell neuroendocrine carcinoma (LCNEC): Safety, pharmacokinetic, and preliminary efficacy results from a phase 1 study [WITHDRAWN]
(ESMO Asia 2025)
- No abstract available
Clinical • P1 data • PK/PD data • Endocrine Cancer • Large Cell Carcinoma • Lung Cancer • Neuroendocrine Carcinoma • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor
April 25, 2024
SNC115 Injections in Patients With Recurrent/Refractory Small Cell Lung Cancer and Lung Large Cell Neuroendocrine Carcinoma
(clinicaltrials.gov)
- P1 | N=35 | Recruiting | Sponsor: Shanghai Simnova Biotechnology Co.,Ltd.
New P1 trial • Endocrine Cancer • Lung Cancer • Neuroendocrine Tumor • Oncology • Small Cell Lung Cancer • Solid Tumor
1 to 3
Of
3
Go to page
1